This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | MicrobiomeTrials
← Back to trials NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Completed PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-04-01Est. Completion: 2026-04-23
Enrollment target: 33 participantsLocations Beijing Cancer Hospital, Beijing, Beijing Municipality, China Fujian Cancer Hospital, Fuzhou, Fujian, China Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China The First Hospital of China Medical University, Shenyang, Liaoning, China Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China Other microbiome trials you might be interested in EGFR Overexpression Locally Advanced Solid Tumor Metastatic Solid Tumor
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Ad…
Seoul, South Korea Est. completion Jun 2027
Recurrent Melanoma (Skin) Metastatic Melanoma Melanoma Stage IV Melanoma Stage III
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therape…
Orange, United States Est. completion Dec 31, 2027
Breast Cancer Solid Tumor
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of…
Boston, United States Est. completion Dec 31, 2026